MAIA

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Wall Street analysts forecast MAIA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAIA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Maia Biotechnology Inc revenue for the last quarter amounts to -9.36M USD, increased 124.31 % YoY.

Maia Biotechnology Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Maia Biotechnology Inc (MAIA) has 13 emplpoyees as of December 15 2025.

Today MAIA has the market capitalization of 50.36M USD.